Genistein inhibits activities of methylenetetrahydrofolate reductase and lactate dehydrogenase, enzymes which use NADH as a substrate by Grabowski, Michał et al.
Accepted Manuscript
Genistein inhibits activities of methylenetetrahydrofolate reductase and lactate
dehydrogenase, enzymes which use NADH as a substrate
Michał Grabowski, Bogdan Banecki, Leszek Kadziński, Joanna Jakóbkiewicz-
Banecka, Rajmund Kaźmierkiewicz, Magdalena Gabig-Cimińska, Grzegorz Węgrzyn,
Alicja Węgrzyn, Dr. Zyta Banecka-Majkutewicz
PII: S0006-291X(15)30394-6
DOI: 10.1016/j.bbrc.2015.08.004
Reference: YBBRC 34377
To appear in: Biochemical and Biophysical Research Communications
Received Date: 30 July 2015
Accepted Date: 1 August 2015
Please cite this article as: M. Grabowski, B. Banecki, L. Kadziński, J. Jakóbkiewicz-Banecka, R.
Kaźmierkiewicz, M. Gabig-Cimińska, G. Węgrzyn, A. Węgrzyn, Z. Banecka-Majkutewicz, Genistein
inhibits activities of methylenetetrahydrofolate reductase and lactate dehydrogenase, enzymes which
use NADH as a substrate, Biochemical and Biophysical Research Communications (2015), doi:
10.1016/j.bbrc.2015.08.004.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Genistein inhibits activities of methylenetetrahydrofolate 1 
reductase and lactate dehydrogenase, enzymes which use 2 
NADH as a substrate 3 
 4 
Michał Grabowskia, Bogdan Baneckia, Leszek Kadzińskia, Joanna Jakóbkiewicz-5 
Baneckab, Rajmund Kaźmierkiewicza, Magdalena Gabig-Cimińskac,  Grzegorz 6 
Węgrzynb, Alicja Węgrzync, Zyta Banecka-Majkutewiczd,* 7 
 8 
 9 
a
 Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of 10 
Gdańsk, Kładki 24, 80-822 Gdańsk, Poland 11 
b
 Department of Molecular Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, 12 
Poland 13 
c
 Laboratory of Molecular Biology (affiliated with the University of Gdańsk), Institute of 14 
Biochemistry and Biophysics, Polish Academy of Sciences, Wita Stwosza 59, 80-308 Gdańsk, 15 
Poland  16 
d
 Department of Neurology, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland 17 
 18 
 19 
 20 
* Corresponding author: 21 
Dr. Zyta Banecka-Majkutewicz 22 
Department of Neurology, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland 23 
Tel. +48 58 349 2314; Fax: +48 58 349 2320 24 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
E-mail: zytabm@gumed.edu.pl 25 
 26 
Abstract 27 
 28 
Genistein (5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a natural 29 
isoflavone revealing many biological activities. Thus, it is considered as a therapeutic 30 
compound in as various disorders as cancer, infections and genetic diseases. Here, we 31 
demonstrate for the first time that genistein inhibits activities of bacterial 32 
methylenetetrahydrofolate reductase (MetF) and lactate dehydrogenase (LDH). Both enzymes 33 
use NADH as a substrate, and results of biochemical as well as molecular modelling studies 34 
with MetF suggest that genistein may interfere with binding of this dinucleotide to the 35 
enzyme. These results have implications for our understanding of biological functions of 36 
genistein and its effects on cellular metabolism. 37 
 38 
Highlights:  39 
- genistein inhibits activities of methylenetetrahydrofolate reductase and lactate 40 
dehydrogenase  41 
- molecular docking confirms that genistein may interfere with the binding site of NADH  42 
- the inhibition is increased when genistein is preincubated with the enzyme and the 43 
dinucleotide 44 
 45 
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 50 
 51 
INTRODUCTION 52 
 53 
5, 7-Dihydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one, commonly known as 54 
genistein, is a natural isoflavone, occurring mostly in leguminous plants [1]. This compound, 55 
preliminarily identified as a phytoestrogen, has been subsequently demonstrated to possess 56 
surprisingly high spectrum of biological activities. Among them, genistein was found to 57 
restore the metabolic balance of bone formation and resorption [2], to alleviate metabolic 58 
problems in obesity and type 2 diabetes, mostly due to its anti-oxidant and anti-inflammatory 59 
features [3], to protect central nervous system against oxidative stress and neuroinflammation 60 
[4], to cause cancer cell growth arrest and apoptosis and to inhibit angiogenesis and 61 
metastasis [5], to halt the growth of some bacteria, including human pathogens [6], and to 62 
inhibit viral infection [7]. Therefore, phytoestrogenic, anti-inflammatory, antiangiogenesis, 63 
antiproliferative, antioxidant, immunomodulatory, pain relief, antibacterial, antiviral and joint 64 
protection properties of genistein led to many proposals of the use this isoflavone in treatment 65 
of various disorders, including cancer as well as metabolic, inflammatory, infectious, 66 
neurological and even genetic diseases [8;9;10;11;12].  67 
The molecular mechanisms of genistein actions are connected mainly to its binding to 68 
estrogen receptors [13; 14], inhibition of tyrosine kinase activities resulting in either 69 
enhancement or impairment of expression of hundreds of genes [15;16], and direct interaction 70 
with topoisomerase II causing modulation of its functions [17; 18]. On the other hand, some 71 
clinical studies indicated that genistein may influence the plasma levels of homocysteine [19; 72 
20; 21], an amino acid that is considered to be a risk factor in cardiovascular diseases and 73 
stroke [4]. Since such effects of the tested isoflavone on homocysteine levels could be hardly 74 
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explained by already known mechanisms of its action, we were searching for possible 75 
explanation of this phenomenon. Therefore, we aimed to test if genistein can influence 76 
activities of enzymes involved in the homocysteine metabolism. One of main enzymes of 77 
homocysteine metabolism is methylenetetrahydrofolate reductase (MTHFR), (EC 1.5.1.20), 78 
catalysing conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which 79 
serves as a methyl donor in the remethylation of homocysteine to methionine [22]. This 80 
enzyme has been conserved during evolution to such extent that specific mutations in the 81 
gene coding for a bacterial homolog (MetF) of the human methylenetetrahydrofolate 82 
reductase (MTHFR) correspond to common polymorphisms in the human gene [23]. 83 
Moreover, products of the wild-type and mutated Escherichia coli (metF) and human 84 
(MTHFR) genes are very similar both structurally [23] and functionally [24]. Therefore, in 85 
our studies, we have employed the E. coli MetF protein as a model.   86 
 87 
 88 
MATERIALS AND METHODS 89 
 90 
Proteins and small molecules 91 
The MetF protein was purified as described previously [25]. Lactate dehydrogenase 92 
(LDH) was purchased from Sigma – Aldrich. Genistein, NADH, menadione and buffer 93 
ingredients were obtained from Sigma - Aldrich 94 
 95 
MetF activity test 96 
MetF activity assay was performed as described previously [25], by measuring a 97 
decrease in absorbance of NADH, consumed during the reaction. The reaction mixture 98 
consisted of 50 mM phosphate buffer containing 10% glycerol and 0.3 mM EDTA, 400 µM 99 
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NADH, and 1.4 mM menadione (vitamin K3 is used as an artificial substrate for MetF). The 100 
activity of MetF was determined by measurement of the kinetics of the reaction at 37oC. The 101 
reaction mixture was prepared without the enzyme, and incubated for 5 min. Following 102 
reaction initiation by the addition of the 0.3 µM enzyme, the measurement was carried out for 103 
30 min, by monitoring the absorbance at a wavelength of 340 nm.  104 
 105 
Effect of genistein on the MetF activity 106 
MetF activity assay in the presence of genistein was performed according to the 107 
standard assay (described above), but genistein was added to the reaction mixture to final 108 
concentrations from 0 to 500 µM. In control experiments, DMSO (a solvent used for 109 
preparation of genistein stock solution) was added to the reaction mixture in the amount 110 
equivalent to that used in the assay with 500 µM genistein. In order to investigate the 111 
mechanism of the enzyme activity inhibition by genistein, the reaction mixture was titrated 112 
with increasing concentrations of this isoflavone, from 0 to 400 µM. The concentrations of 113 
NADH were between 0 and 600 µM. Enzyme reaction kinetics was determined according to 114 
Michaelis–Menten and Lineweaver-Burk equations and plots. 115 
 116 
Influence of reaction initiation factor on genistein-mediated inhibition of MetF activity 117 
Three variants of the test have been developed. First variant assumed preincubation of 118 
genistein, MetF and menadione for 5 min, then NADH was added. Second variant assumed 119 
preincubation of genistein, NADH and menadione for 5 min, then enzyme was added. Third 120 
variant assumed preincubation of genistein, MetF,  and NADH for 5 min. Reaction was 121 
started by the addition of menadione. All tests were performed in reaction buffer (50 mM 122 
phosphate buffer pH 7.2 with 0.3 mM EDTA). 123 
 124 
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Effects of genistein on the activity of lactate dehydrogenase 125 
The commercially available enzyme (lactate dehydrogenase, LDH) was used. LDH 126 
activity was measured by estimation of the decrease in absorbance of NADH consumed 127 
during the reaction. The reaction mixture consisted of the 0.1 µM enzyme, genstein, NADH, 1 128 
mM pyruvate acid and 50 mM phosphate buffer containing 10% glycerol and 0.3 mM EDTA 129 
and genistein in concentration 0 to 500 µM. The reaction was conducted at 37oC. Absorbance 130 
was monitored at 340 nm.  In order to investigate the mechanism of the enzyme activity 131 
inhibition by genistein, reaction mixture was titrated with increasing concentrations of  132 
genistein. The experiment was performed with concentrations of genistein from 0 to 400 µM, 133 
while the concentrations of NADH were between 0 and 1200 µM. Enzyme reaction kinetics 134 
was determined according to Michaelis–Menten and Lineweaver-Burk equations and plots. 135 
 136 
Molecular modeling 137 
The crystal structure of 1ZP3 of Escherichia coli methylenetetrahydrofolate 138 
reductase/FAD complex, which was previously deposited [26] in the Protein Data Bank 139 
(PDB) [27] was used  in our docking experiments. The model of genistein molecule for the 140 
docking procedure was constructed using the Avogadro [http://avogadro.openmolecules.net/] 141 
molecular editing software. We used also the FAD molecule model, which was already 142 
present in the crystal structure of 1ZPT3. The starting geometries of the ligand molecule 143 
models were optimized using the built-in Avogadro minimization algorithm based on the 144 
MMFF94 force field employing the Steepest Descent Algorithm with 500 steps of 145 
minimization. AutoDock Vina [28] was used to perform the molecular docking experiments 146 
with the default optimization parameters offered by the program. The ADT [29; 30] program 147 
from the MGLTools removed non polar hydrogen atoms at the docking simulation preparation 148 
phase. The methylenetetrahydrofolate reductase protein model was treated as a rigid body in 149 
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all docking simulations. For each of the docking experiments, a rectangular grid was 150 
constructed with default value of 1Å grid spacing. It surrounded the enzyme active site. The 151 
sizes of the rectangular grids allowed free movement of the ligands and, for each of the 152 
complex models, were 48Å×46Å×90Å, and the grid centre coordinates were x = -33.804Å, y 153 
= -15.506Å, z = -25.276Å.  The genistein-NADH complex was obtained by using Autodock 154 
Vina software. Autodock Vina [28] docking procedure was used to obtain 2500 sets of low-155 
energy genistein-NADH complexes. Each set consisted of 20 docked low-energy complex 156 
configurations. For such complex, 2500 independent docking runs were performed, obtaining 157 
20 low-energy complexes each time. 158 
 159 
 160 
RESULTS 161 
 162 
The E. coli methylenetetrahydrofolate reductase (MetF) protein has been purified, and 163 
its enzymatic activity was estimated. We found that genistein inhibits the catalyzed  reaction 164 
in the dose-response manner (Fig. 1A). Effects of genistein were observed at concentration as 165 
low as 25 µM, and at 500 µM of genistein, the enzyme activity was almost completely 166 
inhibited. DMSO, a solvent of genistein, had no significant influence on the MetF activity. Km 167 
values of the reactions were calculated as 175, 240, 250, 270 and 300 µM NADH for 0, 50, 168 
100, 200 and 400 µM of genistein, respectively. Vmax values were 0.105, 0.054, 0.048, 0.029, 169 
0.013 M NADH/min, respectively. The Lineweaver-Burk equation identified a mixed type of 170 
inhibition (Fig. 1B). 171 
To determine a possible mechanism for genistein-mediated inhibition of MetF, the 172 
enzymatic activity was measured in reactions preceded by incubation of genistein with 173 
different reaction components. In the case of pre-incubation of genistein with NADH or MetF, 174 
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we observed an inhibitory effect on the enzyme. However, when all three components 175 
(genistein, NADH, MetF) were preincubated, this effect was even more pronounced (Fig. 2). 176 
This suggested the existence of independent interactions: genistein-NADH and genistein-177 
MetF.  178 
To test the hypothesis about direct interactions of genistein with NADH and MetF, we 179 
have conducted molecular docking experiments. Fig. 3A shows the configuration of the 180 
MetF-genistein complex in the presence of FAD in the protein binding site. Fig. 3B depicts all 181 
protein residues interacting directly with the genistein molecule. Three hydrogen bonds 182 
formed between genistein and the backbone nitrogen of Leu277, backbone oxygen of Glu28 183 
and amide oxygen in the side chain of Gln183, should be noted. There are also some other 184 
enzyme residues in the vicinity of genistein molecule: Phe29, Phe30, Thr59, Asp120, Thr227, 185 
Tyr275 and FAD cofactor.  We observed a similar configuration of the 186 
methylenetetrahydrofolate reductase/NADH+FAD complex obtained by docking NADH 187 
molecule into the binding pocket present in 1ZPT enzyme/FAD complex. The RMSD value 188 
between the crystal structure of NADH and the docked molecule, calculated over all heavy 189 
atoms, was equal to 0.20Å, the binding enthalpy of NADH was equal to -7.7 kcal/mol for this 190 
complex. As shown in Fig. 3A, there are multiple hydrogen bonds formed by NAD and amide 191 
bond in the side chain of Gln183. In addition, docking experiment was performed to show 192 
interaction between genistein and NADH. The genistein molecule intercalates between two 193 
parallel NADH rings. This configuration of the genistein-NADH complex is characterized by 194 
the lowest obtained Gibbs interaction free energy value equal to -4.0 kcal/mol. Importantly, 195 
our results of molecular modelling are compatible with the MetF-NADH crystal structure, 196 
reported previously [26]. 197 
Based on the above results, we aimed to test whether methylenetetrahydrofolate 198 
reductase is a specific enzyme that genistein can interact with, or various enzymes using 199 
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NADH as a substrate may be inhibited by this isoflavone. Therefore, we have estimated 200 
activity of another NADH-dependent enzyme, lactate dehydrogenase, in the presence and 201 
absence of genistein. We found that the reaction catalyzed by this enzyme was efficiently 202 
inhibited by genistein (Fig. 4A). Km values of the reactions were calculated as 120, 140, 150, 203 
160 and 175 µM NADH for 0, 50, 100, 200 and 400 µM of genistein, respectively. Vmax 204 
values were 0.106, 0.093, 0.087, 0.080, 0.070 M NADH/min, respectively. The Lineweaver-205 
Burk equation identified a mixed type of inhibition, similarly to the results obtained for MetF 206 
(Fig. 4B). 207 
 208 
 209 
DISCUSSION 210 
 211 
Although genistein is known for its multiple effects on cells and organisms, including 212 
action as a phytoestrogen, inhibition of inflammatory processes, impairment of angiogenesis, 213 
negative regulation of cancer cell proliferation, function as an antioxidant, and inhibition of 214 
bacterial and viral development [7;2;4;1;5] only a few kinds of molecular targets for this 215 
isoflavone have been documented. First, it can bind to estrogen receptors, influencing 216 
reactions dependent on this hormone [13;14]. Second, it inhibits tyrosine kinase activity of 217 
certain transmembrane receptors, thus, impairing signal transduction pathways which regulate 218 
expression of many genes involved in the control of various metabolic processes [15;16]. 219 
Third, it interferes with functions of topoisomerase II which leads to DNA defects and 220 
perturbations in genetic material replication [17;18]. Here, we demonstrate that there are 221 
newly discovered targets of genistein. This isoflavone inhibited activities of two enzymes, 222 
methylenetetrahydrofolate reductase and lactate dehydrogenase. Both these enzymes use 223 
NADH as a substrate.  224 
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The results of docking simulations suggest that genistein molecule forms complexes 225 
with MetF, replacing any molecule accompanying the FAD cofactor. The configurations of 226 
the lowest-energy MetF-genistein complexes depend on the presence of other molecules in 227 
the enzyme active site. For example, the NAD molecule occupies the same binding cleft as 228 
genistein in the enzyme active site, and genistein interacts also with the same residues as 229 
NAD does. Since molecular modelling studies indicated interactions of genistein with the 230 
active centre of MetF, it is likely that the inhibitory properties are due to competition with 231 
NADH for the enzyme binding. Moreover, our molecular modelling tests indicated that 232 
genistein can form complexes with NADH. 233 
 The question appears whether inhibitory effects of genistein on enzymatic activities of 234 
methylenetetrahydrofolate reductase and lactate dehydrogenase can have a physiological 235 
significance. Clinical trials on humans and experiments on animals indicated that genistein is 236 
biocompatible, with no significant adverse effects, even in long-term (several months) use of 237 
its high doses. Examples of such studies include 1-year treatment of children with genistein at 238 
the dose of 150 mg/kg/day [31], 9-month treatment of mice at the dose of 160 mg/kg/day 239 
[32], and 1-year treatment of dogs at the dose of 500 mg/kg/day [33]. On the other hand, 240 
some bacterial species are sensitive to as low genistein concentrations as 10-100 µM [34], 241 
which correspond to doses about 10-100 times lower than those mentioned above in human 242 
and animal studies. Intriguingly, E. coli was found to be resistant to genistein at 243 
concentrations up to 100 µM [34]. Nevertheless, those results are not contradictory to those 244 
presented in this report. First, in the in vitro experiments, MetF revealed still considerable 245 
activity in the presence of genistein at µM (Fig. 1), thus, such residual activity might be 246 
enough to ensure bacterial growth despite partial inhibition by this isoflavone. Second, 247 
permeability of the cell envelope for genistein may be different in different bacterial species, 248 
thus, intracellular concentrations of this compounds can vary between them. In fact, it was 249 
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demonstrated previously that in Vibrio harveryi (a bacterium extremely sensitive to 250 
genistein), the cell envelope permeability for crystal violet (a model molecule in such studies, 251 
which is of similar size to that of genistein) was significantly higher than that in Salmonella 252 
enterica serovar Tiphimurium (a bacterium closely related to E. coli) [35].  253 
Definitely, it appears that some bacteria are significantly more sensitive to genistein 254 
than normal human cells, as no cytotoxicity could be observed in the latter ones at doses up to 255 
100 µM in in vitro studies [36;37]. This is in contrast to cancer cells for which genistein was 256 
cytotoxic at concentrations of 50 µM or lower [38;39]. Therefore, it is possible that genistein-257 
mediated impairment of activities of methylenetetrahydrofolate reductase and/or lactate 258 
dehydrogenase might contribute to antibacterial and anticancer properties of this isoflavone. 259 
Nevertheless, since normal human and animal cells, as well as whole organisms, remain 260 
physiologically unaffected upon the treatment with genistein at doses deleterious for bacteria, 261 
viruses and cancer cells, it is still reasonable to consider this compound as a drug for various 262 
diseases.   263 
 264 
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FIGURE LEGENDS 5 
 6 
Figure 1.  Panel A MetF activity in the presence of increasing concentrations of genistein. In 7 
the experiment shown on panel A, 0.3 µM enzyme was used for each reaction. The activity 8 
measured in the control experiment (without genistein) was assumed to be 100% and other 9 
values reflect this value. The presented results are mean values from three independent 10 
experiments. Error bars represent standard deviation (SD). Panel B represents the kinetics of 11 
MetF-catalyzed  reaction as a Lineweaver-Burk plot.  12 
 13 
Figure 2. MetF activity in reactions initiated by preincubation of various compounds. The 14 
reaction was performed without genistein (control experiment) or with genistein, but with pre-15 
incubation of the pre-mix consisting of either genistein and MetF; genisten and NADH; or 16 
genistein, MetF and NADH, as described in the Materials and Methods. The activity 17 
measured in the control experiment (without genistein) was assumed to be 100%. The 18 
presented results are mean values from three independent experiments. Error bars represent 19 
standard deviation (SD). Statistically significant differences were found between all pairs of 20 
results (p<0.05 in t-test).   21 
 22 
Figure 3. Results of the molecular docking experiment. Panel A: the cartoon showing MetF 23 
residues directly involved in interaction with NADH. The hydrogen bonds are also shown as 24 
the dashed lines with the distance between heavy atoms. Panel B: the cartoon showing protein 25 
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residues directly involved in interaction with genistein (denoted as Lig1). The hydrogen bonds 26 
are also shown as the dashed lines with the distance between heavy atoms. All cartoon 27 
representations of ligands and their binding sites were prepared using LigPlot+ software. 28 
 29 
Figure 4. Panel A LDH activity in the presence of increasing concentrations of genistein. In 30 
the experiment shown on panel A, 0.1 µM enzyme was used for each reaction. The activity 31 
measured in the control experiment (without genistein) was assumed to be 100% and other 32 
values reflect this value. The presented results are mean values from three independent 33 
experiments. Error bars represent standard deviation (SD). Panel B represents the kinetics of 34 
LDH-catalyzed  reaction as a Lineweaver-Burk plot.  35 
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Figure 4 68 
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